The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study
Drug Safety · 2024
DOI: 10.1007/s40264-024-01427-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Drug Safety, 2024. Verfasst von Ying Li und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China. Hauptthemen laut MEDLINE: Psoriasis, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Eli Lilly and Company.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Shanghai Skin Disease Hospital, Tongji University School of Medicine, Shanghai, 200443, China.
- Department of Dermatology, Longgang Central Hospital of Shenzhen, Shenzhen, Guangdong, China.
- Department of Dermatology, Dalian Skin Disease Hospital, Dalian , Liaoning, China.
- Department of Dermatology, Ningbo First Hospital, Ningbo, Zhejiang, China.
- Department of Dermatology, Wuhan Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China.
- Department of Dermatology, General Hospital of Ningxia Medical Hospital, Yinchuan, Ningxia, China.
Förderung
- Eli Lilly and Company
Zitieren
APA
Li, Y., Dang, L., Lv, C., Lin, B., Tao, J., Yu, N., Deng, Y., Wang, H., Kang, X., Qin, H., Chen, R., Li, J., Liang, Y., Liang, Y., & Shi, Y. (2024). The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug Safety. https://doi.org/10.1007/s40264-024-01427-3
Vancouver
Li Y, Dang L, Lv C, Lin B, Tao J, Yu N, et al. The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study. Drug Safety. 2024. doi:10.1007/s40264-024-01427-3
BibTeX
@article{Li2024,
author = {Li, Ying and Dang, Lin and Lv, Chengzhi and Lin, Bingjiang and Tao, Juan and Yu, Nan and Deng, Ya and Wang, Huiping and Kang, Xiaojing and Qin, Hui and Chen, Rong and Li, Jinnan and Liang, Yunsheng and Liang, Yanhua and Shi, Yuling},
title = {The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study},
journal = {Drug Safety},
year = {2024},
doi = {10.1007/s40264-024-01427-3}
}
EUVIMED